What's Happening?
Lactiga US, Inc. has received NIH funding to advance its development of a breastmilk-derived antibody for treating inflammatory bowel disease (IBD). The company's secretory IgA (sIgA) antibody, purified from human breastmilk, aims to address immune system dysregulation and inflammation in the gut. The therapy is designed to neutralize antigens, strengthen epithelial barriers, and minimize adverse events. IBD affects nearly 3 million Americans, with current treatments being costly and often ineffective. Lactiga's research, in collaboration with Baylor College of Medicine, seeks to establish a new class of oral mucosal immunotherapies.
Why It's Important?
Lactiga's innovative approach to IBD treatment using breastmilk-derived antibodies represents a significant advancement in addressing chronic diseases. The NIH funding supports the development of therapies that leverage natural immune system attributes, potentially offering safer and more effective alternatives to existing treatments. This research could lead to breakthroughs in managing IBD and other immune-related conditions, reducing healthcare costs and improving patient outcomes. The focus on mucosal immunity highlights the potential for novel therapeutic strategies in treating complex diseases.
